Flow Cytometry
Flow Cytometry
批准号:
7695941
负责人:
MICHAEL ANDREEFF
金额:
$35.96万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-28 至 2013-06-30
关键词:
5-(6)-carboxyfluorescein diacetate succinimidyl esterAntigensApoptosisArtsBIRC4 geneBiological AssayBromodeoxyuridineCancer CenterCancer Center Support GrantCancer Immunology ScienceCaspaseCell divisionCellsClinical ResearchCommunitiesConfocal MicroscopyCore FacilityCyclinsDNADetectionDevelopmentEmployeeEnvironmentEventFacultyFlow CytometryFluorescence-Activated Cell SortingFundingFutureGalactosidaseGoalsGrantGreen Fluorescent ProteinsGrowth FactorHourImage AnalysisImmunologyLaboratoriesLaser MicroscopyLaser Scanning CytometryLasersLifeMalignant - descriptorMembrane PotentialsMethodsMicroscopyMissionMitochondriaMolecularMolecular CytogeneticsMolecular and Cellular BiologyMultiparametric AnalysisNCI Center for Cancer ResearchNGFR ProteinNerve Growth Factor ReceptorsNormal CellNumbersOperative Surgical ProceduresPCNA genePaperPeer ReviewPeer Review GrantsPhenotypePrincipal InvestigatorProteinsPublishingRecording of previous eventsRegulationReproduction sporesResearchResearch ActivityResearch PersonnelResidual NeoplasmScientistServicesSignal TransductionSiteSorting - Cell MovementStem cell transplantStem cellsSystemTP53 geneTechniquesTechnologyTimeTravelcancer cellcancer immunology functioncancer preventioncell analyzercellular imagingdigitalfluorescence activated cell sorter deviceinstrumentleukemiamalignant breast neoplasmmelanomamemberpeerprogenitorprogramssingle cell analysistransgene expressiontumorigenesis
中文摘要
流式细胞术和细胞成像核心设施(FCCICF)为研究人员提供细胞分析
英文摘要
The Flow Cytometry and Cellular Imaging Core Facility (FCCICF) provides cellular analysis to investigators
with peer-reviewed grants. The FCCICF has two sites, on the north campus and on the recently-opened
south campus. It occupies 1900 sq. ft. and is directed by Dr. Michael Andreeff. The FCCICF develops and
provides techniques for single-cell analysis. Cell phenotyping, proliferation, signaling and apoptosis assays
have been established and modified for multiparametric analysis. Immunophenotypic analysis was combined
with assays of intracellular proteins related to apoptosis (Bcl-2, Bcl-XL, BAG-1, p53, Rb, caspase activation,
mitochondria! membrane potential and Fas), cell signaling (MARK), proliferation (Ki67, cyclins, BrDU, PCNA,
DNA) and cell division history (CFSE). Quantitation of cellular antigens allows determination of the antibodybinding
capacity per cell. Rare events and progenitor/stem cell subpopulations can be detected and isolated
by three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysis
by molecular cytogenetic and other molecular techniques including quantitation of intracellular PKCoc, Bax,
Bcl-2, ERK, pERK, XIAP by laser scanning cytometry. FISH has been combined with apoptosis assays to
discriminate apoptosis in normal and malignant cells. The number, phenotype and proliferation of minimal
residual disease cells can be determined at levels of one malignant in 30,000 normal cells. Methods for
detection of transgene expression in cells are in place using p-galactosidase (p-gal), nerve growth factor
receptor (NGF-R), and green fluorescent protein (EGFP). Acquisition of 3 new FACS Aria cell sorters and a
four-laser flow cytometer (B&D LSRII) has upgraded the facility to provide state-of-the-art isolation and
analysis. Laser confocal microscopy has been used extensively and was upgraded by acquisition of an
Olympus FV-500 multi-user instrument and a DSU spinning disc confocal system. High-impact studies in
cancer prevention, growth factor signaling in breast cancer, apoptosis regulation in leukemias and multistep
tumorigenesis all utilized confocal microscopy. The FCCICF now utilizes 17 major instrument systems. The
Core supports numerous R01, P01, R21, and SPORE grants. Since the previous review, the number of
users has increased 145% (169 investigators with peer-reviewed grants from 19 different programs). 67% of
users have peer-reviewed funding. During the previous funding period, 11,668 hours of service was
provided. Use has tripled to greater than 7,000 hours estimated for 2007. Future plans are focused on the
continued development and application of cutting-edge technologies in cell analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
-
批准号:10356325
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2022
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
-
批准号:10550265
-
项目类别:
-
资助金额:$22.27万
-
财政年份:2022
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
-
批准号:10663157
-
项目类别:
-
资助金额:$37.37万
-
财政年份:2019
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
-
批准号:9806956
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2019
-
负责人:MICHAEL ANDREEFF
-
依托单位:
P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
-
批准号:8499746
-
项目类别:
-
资助金额:$19.63万
-
财政年份:2013
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
-
批准号:7897533
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2010
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
-
批准号:8056055
-
项目类别:
-
资助金额:$31.22万
-
财政年份:2010
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Targeting Microenvironment / Leukemia Cell Interactions in CML
-
批准号:8000073
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2010
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma
-
批准号:7715218
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2009
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
-
批准号:7936811
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2009
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
-
批准号:8324135
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2009
-
负责人:MICHAEL ANDREEFF
-
依托单位:
P53 Activation as Novel Therapeutic Stratgey for Acute Myelogenous Leukemia
-
批准号:7468678
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2008
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Treatment of Metastatic Breast Cancer with Gene Modified Mesenchymal Stem Cells
-
批准号:7737051
-
项目类别:
-
资助金额:$21.97万
-
财政年份:2008
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Fluorescence-Activated Cell Sorting (FACS) and Molecular Cytogenetics (FISH)
-
批准号:7270271
-
项目类别:
-
资助金额:$14.64万
-
财政年份:2007
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Targeting Regulators of Apoptosis in AML
-
批准号:7270264
-
项目类别:
-
资助金额:$34.58万
-
财政年份:2007
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Anti-Leukemic Activity of the Novel Triterpeniod CDDO
-
批准号:6649746
-
项目类别:
-
资助金额:$23.49万
-
财政年份:2002
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Anti-Leukemic Activity of the Novel Triterpeniod CDDO
-
批准号:6470779
-
项目类别:
-
资助金额:$25.38万
-
财政年份:2002
-
负责人:MICHAEL ANDREEFF
-
依托单位:
Anti-Leukemic Activity of the Novel Triterpeniod CDDO
-
批准号:6796771
-
项目类别:
-
资助金额:$25.18万
-
财政年份:2002
-
负责人:MICHAEL ANDREEFF
-
依托单位:
CORE--AUTOMATED CYTOMETRY & CELL SORTER LABORATORY/CONFOCAL MICROSCOPY
-
批准号:6481853
-
项目类别:
-
资助金额:$25.41万
-
财政年份:2001
-
负责人:MICHAEL ANDREEFF
-
依托单位:
CORE--AUTOMATED CYTOMETRY & CELL SORTER LABORATORY/CONFOCAL MICROSCOPY
-
批准号:6347265
-
项目类别:
-
资助金额:$25.41万
-
财政年份:2000
-
负责人:MICHAEL ANDREEFF
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: